Pfizer Shares Up 11.3% While Facing 2026-2030 LOE Cliff
Pfizer’s stock has risen 11.3% over the past six months, trailing the 24.4% gain of the large cap pharmaceuticals industry, as COVID-product revenues decline. Upcoming patent expirations on drugs such as Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi pose a 2026-2030 LOE cliff that new launches and acquisitions must offset.
1. Recent Stock Performance
Pfizer’s stock has climbed 11.3% over the past six months, underperforming the 24.4% gain of the large cap pharmaceuticals industry as sales of its COVID-19 products decline sharply.
2. Patent Expirations and LOE Risks
Several of Pfizer’s top-selling drugs—including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi—face patent expirations between 2026 and 2030, creating a looming loss of exclusivity cliff that could significantly impact revenues.
3. Non-COVID Revenue and Pipeline Outlook
Operational revenues excluding COVID products have shown improvement, driven by growth in Vyndaqel, Padcev and Eliquis, as well as contributions from recent product launches and acquisitions, which Pfizer expects to help restore top-line growth late in the decade.